Laryngeal transplantation in the setting of cancer: A rat model

Laryngoscope

Volumn 118, Issue 12, 2008, Pages 2166-2171

  Shipchandler, Taha Z ^a,b   Lorenz, Robert R ^a   Lee, Walter T ^a   Teker, Aysenur Meric ^a   Dan, Olivia ^a   Strome, Marshall ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Head and Neck Institute   (United States)

Author keywords

Everolimus; Laryngeal transplantation; Rat; Squamous cell carcinoma; Tumor cell line

Indexed keywords

EVEROLIMUS; TACROLIMUS; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CARCINOMA CELL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; EXPERIMENTAL NEOPLASM; GRAFT REJECTION; IMMUNOSUPPRESSIVE TREATMENT; LARYNX CANCER; LARYNX TRANSPLANTATION; LOW DRUG DOSE; LUNG METASTASIS; MALE; MICROEMULSION; MONOTHERAPY; NONHUMAN; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RAT; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; ANIMAL; CANCER TRANSPLANTATION; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG COMBINATION; FISCHER 344 RAT; GRAFT SURVIVAL; LARYNGECTOMY; LARYNX; LARYNX TUMOR; LUNG TUMOR; METASTASIS; ORAL DRUG ADMINISTRATION; PATHOLOGY; TRANSPLANTATION; TUMOR CELL LINE; TUMOR RECURRENCE;

ADMINISTRATION, ORAL; ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE AGENTS; LARYNGEAL NEOPLASMS; LARYNGECTOMY; LARYNX; LUNG NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM TRANSPLANTATION; RATS; RATS, INBRED F344; SIROLIMUS; TACROLIMUS;

EID: 58149360514     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLG.0b013e3181855108     Document Type: Article

References (19)

1. Strome M., Stein J., Esclamado R., et al. Laryngeal transplantation and 40-month follow-up. N Engl J Med 2001; 344: 1676-1679.
2. Potter CP, Birchall MA. Laryngectomees' views on laryngeal transplantation. Transpl Int 1998; 11:433-438.
3. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl 1998; 147-157.
4. Stallone G., Schena A., Infante B., et al. Sirolimus for Kaposi's sarcoma in renal transplant recipients. N Engl J Med 2005; 352:1317-1323.
5. Zhou J., Fan J., Wang Z., et al. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: report of an initial experience. World J Gastroenterol 2006; 12:3114-3118.
6. Mabuchi S., Altomare DA, Cheung M., et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 2007; 13: 4261-4270.
7. Fernandez A., Marcen R., Pascual J., et al. Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia. Transpl Proc 2006; 38:2453-2455.
8. Khariwala SS, Kjaergaard J., Lorenz R., van Lente F., Shu S., Strome M. Everolimus (RAD) inhibits in vivo growth of murine squamous cell carcinoma (SCC VII). Laryngoscope 2006; 116:814-820.
9. Schuler W., Sedrani R., Cottens S., et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997; 64:36-42.
10. Neuhas P., Klupp J., Langrehr JM. mTOR inhibitors: an overview. Liver Transpl 2001; 7:473-484.
11. Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol 1996; 14:483-510.
12. Hoyer PF, Ettenger R., Kovarik JM, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. Transplantation 2003; 75: 2082-2085.
13. Eisen HJ, Tuzcu EM, Dorent R., et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant recipients. N Engl J Med 2003; 349:847-858.
14. Khariwala SS, Knott PD, Dan O., Klimczak A., Siemionow M., Strome M. Pulsed immunosuppression with everolimus and anti-alphabetaTCR: laryngeal allograft preservation at 6 months. Ann Otol Rhinol Laryngol 2006; 115:74-80.
15. Nagamine K., Ozaki N., Shinoda M., et al. Mechanical allodynia and thermal hyperalgesia induced by experimental squamous cell carcinoma of the lower gingival in rats. J Pain 2006; 7:659-670.
16. Lorenz RR, Dan O., Fritz MA, Nelson M., Strome M. Rat laryngeal transplant model: technical advancements and a redefined rejection grading system. Ann Otol Rhinol Laryngol 2002; 111:1120-1127.
17. McGeown MG, Douglas JF, Middleton D. One thousand renal transplants at Belfast City Hospital: post-graft neoplasia 1968-1999, comparing azathioprine only with cyclosporinebased regimens in a single centre. Clin Transpl 2000: 193-202.
18. Jonas S., Rayes N., Neumann U., et al. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer 1997; 80:1141-1150.
19. Muir G., Rajbabu K., Callen C., Fabre JW. Preliminary evidence that the allogeneic response might trigger antitumour immunity in patients with advanced prostate cancer. BJUInt 2006; 98:989-995.